％0期刊文章％A VENTETUOLO，COREY E.％A ALIOTTA，JASON M.％A Braza，Julie％Chichger，Hauvi％A Dooner，Mark％A Mcuirl，Donald％A Mullin，Christopher J.％A Newton，Julie％A Pereira，Mandy％A Princiotto，amy％a quesenberry，彼得J.％A Walsh，Thomas％A Whitthall，Mary％A Klinger，James R.％A Harrington，伊丽莎白o.％T肺动脉内皮细胞的培养物肺动脉导管气球提示：用于肺血管疾病的考虑因素D 2020％R 10.1183-2019％J欧洲呼吸期轴颈％P 1901313％x内皮功能障碍是肺动脉高压（PAH）的标志，但没有建立研究生物患者肺动脉内皮细胞（PAEC）的方法。我们试图从右心导管（RHC）期间使用的肺动脉导管（PAC）气球培养PAEC，以表征成功的培养尝试并描述PAEC行为。Paecs在原发性培养中生长到汇合和内皮细胞表型证实。在3-8段之间进行凋亡，迁移和管形成的标准测定。从19名（39％）的气球中，我们收集了49个PAC秘诀，从45名受试者中获得了成功的PAEC文化。在成功与不成功的尝试中，主体人口统计或RHC程序细节没有差异。成功的较高但不显着的比例（10/19,53％）与遇到PAH的血流动力学标准的受试者的失败（9/30,30％）（p = 0.10）。在心脏指数较低的受试者（P = 0.03）和更高的肺血管阻力（P = 0.04）中，成功的培养物更有可能。 PAECs from a subject with idiopathic PAH were apoptosis resistant compared to commercial PAECs (p=0.04) and had reduced migration compared to PAECs from a subject with portopulmonary hypertension with high cardiac output (p=0.01). PAECs from a subject with HIV-associated PAH formed fewer (p=0.01) and shorter (p=0.02) vessel networks compared to commercial PAECs.Sustained culture and characterisation of PAECs from RHC balloons is feasible, especially in PAH with high hemodynamic burden. This technique may provide insight into endothelial dysfunction during PAH pathogenesis.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ventetuolo reports grants from National Institutes of Health , during the conduct of the study; grants from United Therapeutics and Eiger to her institution, personal fees from Acceleron Pharma, outside the submitted work; and Spouse is an employee of CVS Health.Conflict of interest: Dr. Aliotta has nothing to disclose.Conflict of interest: Dr. Braza has nothing to disclose.Conflict of interest: Dr. Chichger has nothing to disclose.Conflict of interest: Dr. Dooner has nothing to disclose.Conflict of interest: Dr. McGuirl has nothing to disclose.Conflict of interest: Dr. Mullin has nothing to disclose.Conflict of interest: Dr. Newton has nothing to disclose.Conflict of interest: Dr. Pereira has nothing to disclose.Conflict of interest: Dr. Princiotto has nothing to disclose.Conflict of interest: Dr. Quesenberry has nothing to disclose.Conflict of interest: Dr. Walsh has nothing to disclose.Conflict of interest: Dr. Whittenhall has nothing to disclose.Conflict of interest: Dr. Klinger has nothing to disclose.Conflict of interest: Dr. Harrington has nothing to disclose. %U //www.qdcxjkg.com/content/erj/early/2019/12/12/13993003.01313-2019.full.pdf